ZVRA ZEVRA THERAPEUTICS, INC.companySEC Filings & Insider Trading Activity 2026
Latest ZEVRA THERAPEUTICS, INC. (ZVRA) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 9, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on March 16, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for ZEVRA THERAPEUTICS, INC. (ZVRA) (SEC CIK 1434647), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • Zevra Therapeutics issued a press release March 16, 2026 announcing an unspecified "Agreement" — full details in Exhibit 99.1
- • Nature and financial terms of the Agreement not disclosed in this item; investors should review Exhibit 99.1 for deal specifics
Item 1.02: Termination of a Material Definitive Agreement
- • Full repayment of $63.0M outstanding principal (including ~$3.0M accrued PIK interest) plus cash interest on March 12, 2026
- • Original facility: $100.0M senior secured, $60.0M drawn at inception (April 2024); early repayment ~3 years ahead of April 2029 maturity
Item 1.01: Entry into a Material Definitive Agreement
- • Zevra sells entire SDX portfolio (AZSTARYS/KP415, KP1077) to Commave for $50M total cash — deal closed March 13, 2026
- • Payment structure: $25M at signing, $20M within ~10 business days, $5M upon delivery of manufacturing/patent records
Item 2.02: Results of Operations and Financial Condition
- • Q4 2025 earnings release issued March 9, 2026 — full financial results and corporate updates in Exhibit 99.1
- • Conference call/webcast scheduled March 9, 2026 at 4:30 p.m. ET to discuss results
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • Justin Renz appointed CFO effective March 9, 2026; seasoned biopharma CFO with prior roles at Ardelyx, Correvio, and Karyopharm
- • Base salary $520,000 with 45% annual bonus target (~$234,000 target bonus)
Recent 8-K FilingsCurrent Reports
AI-powered analysis of ZEVRA THERAPEUTICS, INC. (ZVRA) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 16, 2026 | — | Analysis | — |
8-K | Mar 9, 2026 | — | Analysis | — |
10-K | Mar 9, 2026 | Dec 31, 2025 | — | |
8-K | Dec 17, 2025 | — | — | |
8-K | Dec 2, 2025 | — | — | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 12, 2025 | Jun 30, 2025 | — | |
10-Q | May 13, 2025 | Mar 31, 2025 | — | |
10-K | Mar 12, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 13, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 14, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Apr 1, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 7, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 14, 2023 | Jun 30, 2023 | — | |
10-Q | May 15, 2023 | Mar 31, 2023 | — | |
10-K | Mar 7, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 10, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 12, 2022 | Jun 30, 2022 | — | |
10-Q | May 12, 2022 | Mar 31, 2022 | — | |
10-K | Mar 31, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 10, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 13, 2021 | Jun 30, 2021 | — | |
10-Q | May 14, 2021 | Mar 31, 2021 | — | |
10-K | Mar 12, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest ZVRA SEC filings in 2026?
ZEVRA THERAPEUTICS, INC. (ZVRA) has filed a 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on March 16, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ZVRA file its most recent 10-K annual report?
ZEVRA THERAPEUTICS, INC. (ZVRA) filed its most recent 10-K annual report on March 9, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ZVRA 10-Q quarterly reports?
ZEVRA THERAPEUTICS, INC. (ZVRA)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every ZVRA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ZVRA filed recently?
ZEVRA THERAPEUTICS, INC. (ZVRA)'s most recent 8-K was filed on March 16, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ZVRA insider trading activity (Form 4)?
SignalX aggregates every ZVRA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does ZVRA file with the SEC?
ZEVRA THERAPEUTICS, INC. (ZVRA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ZVRA filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ZEVRA THERAPEUTICS, INC. (ZVRA).
What is ZVRA's SEC CIK number?
ZEVRA THERAPEUTICS, INC. (ZVRA)'s SEC CIK (Central Index Key) number is 1434647. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1434647 to look up all ZVRA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ZVRA return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from ZEVRA THERAPEUTICS, INC. (ZVRA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of ZEVRA THERAPEUTICS, INC. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 48+ filings.